CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-label, Phase II, Multi-cohort, 2-stage Trial to Evaluate the Efficacy and Safety of Regorafenib in Combination With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Pretreated Solid Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05582031
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:07.602647+00:00
Published At: 2023-06-07T00:00:00+00:00
Record Updated At: 2023-06-07
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Anal Squamous Cell Carcinoma", "Colorectal Neoplasms", "Soft Tissue Sarcoma", "Malignant Pleural Mesothelioma", "Small Cell Lung Carcinoma", "Castrate Resistant Prostate Cancer", "Neuroendocrine Carcinoma of Prostate", "Gastroenteropancreatic Neuroendocrine Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-06-07"
protocolSection.identificationModule.nctId: "NCT05582031"
protocolSection.identificationModule.officialTitle: "An Open-label, Phase II, Multi-cohort, 2-stage Trial to Evaluate the Efficacy and Safety of Regorafenib in Combination With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Pretreated Solid Cancers"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.